- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-211682) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, |
| (2) | Registration Statement (Form S-8 No. 333-216412) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, |
| (3) | Registration Statement (Form S-8 No. 333-223407) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, |
| (4) | Registration Statement (Form S-8 No. 333-229954) pertaining to the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, |
| (5) | Registration Statement (Form S-8 No. 333-232009) pertaining to Reata Pharmaceuticals, Inc. Second Amended and Restated Long Term Incentive Plan, |
| (6) | Registration Statement (Form S-3 No. 333-218915) and in the related Prospectus, and |
| (7) | Registration Statement (Form S-3 No. 333-226289) and in the related Prospectus; |
of our reports dated February 19, 2020, with respect to the consolidated financial statements of Reata Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Reata Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Reata Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Dallas, Texas
February 19, 2020